• Alias: AP26113
    • A broad-spectrum multikinase inhibitor with activity against ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3, as well as EGFR deletion and point mutations. ALK autophosphorylation and ALK-mediated phosphorylation of downstream signaling proteins STAT3, AKT, ERK1/2, and S6 are inhibited by brigatinib.
    • FDA approved for metastatic NSCLC with ALK(+) who have progressed on, or are intolerant to, crizotinib.
    • Recommended dose: 90 mg PO daily for 7 days. If tolerated, may continue to full dose at 180 mg PO daily until disease progression. If therapy is interrupted for 14 days 90 mg PO daily for days and then increase
    Other topics in Targeted and Immunotherapy Agents